Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Fourth Quarter twenty twenty five Financial Results and Business Update Conference Call. At this time, all participants are in a listen only mode. Following the formal remarks, we will open up the call for your questions. I would now like to turn the call over to Janae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed. Great. Thank you, operator. Good afternoon, everyone, and welcome to Atea Pharmaceuticals fourth quarter and full year twenty twenty five financial results and business update conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at ir.ateapharma.com. With me today from Atea are our Chief Executive Officer and Founder, Doctor. John Pierre Somodosi Chief Development Officer, Doctor. Janet Hammond Chief Commercial Officer, John Babrika Chief Medical Officer, Doctor. Aroncha Horgan and Chief Financial Officer and Executive Vice President of Legal, Andrea Porcren, who will be available for the Q and A portion of today's call. Before we begin the call and as outlined on Slide two, I would like to remind you that today's discussion will contain forward looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean Pierre. Thank you, J...